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Abstract 
Background: X-linked muscular dystrophy is a primary disease of the neuromuscular system. Primary abnormalities 
in the Dmd gene result in the absence of the full-length isoform of the membrane cytoskeletal protein dystrophin. 
Besides progressive skeletal muscle wasting and cardio-respiratory complications, developmental cognitive deficits 
and behavioural abnormalities are clinical features of Duchenne muscular dystrophy. In order to better understand 
the mechanisms that underlie impaired brain functions in Duchenne patients, we have carried out a proteomic analy-
sis of total brain extracts from the mdx-4cv mouse model of dystrophinopathy.
Results: The comparative proteomic profiling of the mdx-4cv brain revealed a significant increase in 39 proteins and 
a decrease in 7 proteins. Interesting brain tissue-associated proteins with an increased concentration in the mdx-4cv 
animal model were represented by the glial fibrillary acidic protein GFAP, the neuronal Ca2+-binding protein calretinin, 
annexin AnxA5, vimentin, the neuron-specific enzyme ubiquitin carboxyl-terminal hydrolase isozyme L1, the dendritic 
spine protein drebrin, the cytomatrix protein bassoon of the nerve terminal active zone, and the synapse-associated 
protein SAP97. Decreased proteins were identified as the nervous system-specific proteins syntaxin-1B and syntaxin-
binding protein 1, as well as the plasma membrane Ca2+-transporting ATPase PMCA2 that is mostly found in the brain 
cortex. The differential expression patterns of GFAP, vimentin, PMCA2 and AnxA5 were confirmed by immunoblotting. 
Increased GFAP levels were also verified by immunofluorescence microscopy.
Conclusions: The large number of mass spectrometrically identified proteins with an altered abundance suggests 
complex changes in the mdx-4cv brain proteome. Increased levels of the glial fibrillary acidic protein, an intermediate 
filament component that is uniquely associated with astrocytes in the central nervous system, imply neurodegener-
ation-associated astrogliosis. The up-regulation of annexin and vimentin probably represent compensatory mecha-
nisms involved in membrane repair and cytoskeletal stabilization in the absence of brain dystrophin. Differential 
alterations in the Ca2+-binding protein calretinin and the Ca2+-pumping protein PMCA2 suggest altered Ca2+-han-
dling mechanisms in the Dp427-deficient brain. In addition, the proteomic findings demonstrated metabolic adapta-
tions and functional changes in the central nervous system from the dystrophic phenotype. Candidate proteins can 
now be evaluated for their suitability as proteomic biomarkers and their potential in predictive, diagnostic, prognostic 
and/or therapy-monitoring approaches to treat brain abnormalities in dystrophinopathies.
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Background
Proteome-wide studies play a central role in the system-
atic assessment of diseases of childhood. Biomedical 
surveys based on mass spectrometry-based proteom-
ics can provide a comprehensive overview of molecular 
changes that underlie paediatric disorders and identify 
novel proteomic biomarker candidates for improving 
predictive, diagnostic, prognostic and therapy-monitor-
ing procedures [1–3]. Duchenne muscular dystrophy is a 
paediatric disease of the skeletal musculature that is char-
acterized by a variety of abnormalities in muscle tissues, 
including changes in myofibre size, central nucleation, 
fibre branching, hyper-contractility, necrosis, inflamma-
tion, fatty deposition and myofibrosis [4–6]. Mutations 
or genetic rearrangements in the X-chromosomal Dmd 
gene encoding the membrane cytoskeletal protein dys-
trophin are the underlying cause for highly progressive 
skeletal muscle wasting [7]. The reduction in dystrophin-
associated glycoproteins is a hallmark of fibre degen-
eration and closely linked to the loss of sarcolemmal 
integrity in muscular dystrophy [8–10]. Associated com-
plications in Duchenne patients are cardio-respiratory 
impairments, orthopaedic problems causing muscle con-
tractures and scoliosis, endocrinological issues related to 
growth and weight gain, as well as gastrointestinal, renal, 
urinary and ophthalmological complications [11–14] that 
are taken into account in the current treatment and man-
agement of dystrophinopathies [15–17].
The elucidation of the molecular and cellular mecha-
nisms of the multi-systemic manifestation of Duchenne 
muscular dystrophy in non-muscle tissues is compli-
cated by the existence of several promoters that drive 
the tissue-specific expression of dystrophin isoforms 
ranging in molecular mass from 71 to 427  kDa [18]. 
Brain dystrophins and their associated glycoproteins 
are mainly involved in neuronal excitability, signal inte-
gration, synaptic modulation and neuronal plasticity 
[19–22]. In the nervous system, major dystrophin iso-
forms include Dp71, Dp140 and Dp427 [23]. Full-length 
brain dystrophins are present in neurons of the cerebral 
cortex and the hippocampus, as well as in cerebellar 
Purkinje cells [24–27] and exhibit similar biochemi-
cal properties as the muscle Dp427 isoform [28, 29]. 
The shorter dystrophin isoform Dp140 is most highly 
expressed during brain development [30] and the most 
abundant brain dystrophin, Dp71, is present in both 
neurons and glia cells in the dentate gyrus and the olfac-
tory bulb [31–33].
The presence of specific dystrophins in the central 
nervous system is of considerable interest, since cognitive 
impairments and emotional disturbances are established 
clinical features of dystrophinopathies [34–36]. Mental 
retardation and behavioural impairments seem to be sec-
ondary to physical handicap [37–40] and do not correlate 
with the progressive nature of the neuromuscular pathol-
ogy in X-linked muscular dystrophy [41–44]. Cognitive 
impairments seem to affect memory, attention, language 
and emotion to a differing degree in individuals suffering 
from dystrophinopathies [45–47]. In analogy to Duch-
enne patients, the mdx animal model of dystrophinopa-
thy shows significant alterations in associative learning 
patterns and deficits in long-term consolidation memory 
[48–50], as well as metabolic and cellular abnormalities 
in distinct brain regions [51–53].
In order to evaluate the degree of proteome-wide 
changes in the central nervous system of the dystrophin-
deficient mouse, we have carried out a comparative label-
free mass spectrometric analysis of the mdx-4cv brain 
versus wild type brain. Systematic proteomic studies have 
previously established a number of changes in proteins 
involved in energy metabolism, cellular signalling, the 
extracellular matrix, cytoskeletal networks and the cellu-
lar stress response in dystrophic skeletal and cardiac mus-
cles [54]. Here, we have applied this technology-driven 
approach to extend these studies to the pathophysiologi-
cal mechanisms that facilitate impaired brain functions 
in X-linked muscular dystrophy. Highly relevant proteins 
affected in brain tissue from dystrophic mice were identi-
fied as the glial fibrillary acidic protein GFAP, calretinin, 
annexin AnxA5, vimentin, syntaxin, drebrin, bassoon 
and the plasma membrane Ca2+-ATPase PMCA2.
Results and discussion
Intellectual impairments and emotional disturbances 
are clearly present in Duchenne patients [45], although 
these clinical features are non-progressive and do not 
affect all dystrophic children [37]. Besides the unknown 
mechanisms that underlie this differential occurrence of 
neurological issues within the Duchenne patient cohort, 
other crucial unanswered questions remain in relation to 
the molecular and cellular pathogenesis of brain abnor-
malities. Importantly, it is not currently clear whether 
a pathophysiological hierarchy exists between devel-
opmental issues on the one hand and cycles of neuro-
degeneration and astroglyosis on the other hand in the 
central nervous system of patients afflicted with X-linked 
Keywords: Annexin, Ca2+-ATPase PMCA2, Dystrophinopathy, Glial fibrillary acidic protein, Glyosis, Intermediate 
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muscular dystrophy [46]. It was therefore of interest 
to use an unbiased and technology-driven approach 
to attempt a systematic evaluation of proteome-wide 
changes in affected brain tissue. In general, comparative 
proteomics has the potential to identify complex changes 
within cellular systems on a more global basis as com-
pared to individual and hypothesis-driven biochemical, 
cell biological or physiological investigations. The prot-
eomic profiling of the mdx-4cv brain presented here has 
successfully detected significant changes in a number of 
representative serum and brain proteins.
Label‑free LC–MS/MS analysis of mouse brain extracts
An overview of the comparative proteomic analysis of 
the wild type brain versus the mdx-4cv brain employ-
ing label-free mass spectrometry is given in Fig.  1. The 
proteomic assessment of the mouse brain identified 4878 
unique peptides belonging to 1359 individual protein 
species in the wild type and 4311 unique peptides belong-
ing to 1213 individual protein species in the mdx-4cv 
phenotype. The fact that this technique was successfully 
applied to study the mouse brain proteome is exemplified 
by the mass spectrometric identification of 2 well-estab-
lished brain proteins, BASP-1 and SNP-25. The growth-
associated brain acid soluble protein BASP-1 (Q91XV3; 
also known as neuronal axonal membrane protein NAP-
22) is a membrane-attached signalling protein of growth 
cones that form the tips of elongating axons [55]. Its 
sequence was covered in the wild type brain by 16 unique 
peptides with 87  % coverage and in the mdx-4cv brain 
by 17 unique peptides with 87 % coverage. The synapto-
some-associated protein SNP-25 (P60879) is associated 
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Fig. 1 Overview of the proteomic strategy to determine global changes in the protein constellation of the mdx-4cv brain. The flow chart outlines 
the comparative analysis of wild type versus mdx-4cv brain extracts and shows the mass spectrometric fingerprint of the glial fibrillary acidic protein 
GFAP as a major finding of this proteomic study
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with proteins involved in vesicle docking and membrane 
fusion and plays a critical role in synaptic function and 
the molecular regulation of neurotransmitter release [56]. 
SNP-25 was covered in the wild type brain by 13 unique 
peptides with 47  % coverage and in the mdx-4cv brain 
by 11 unique peptides with 46 % coverage. In contrast to 
gel-based studies, the usage of liquid chromatography in 
combination with highly sensitive label-free mass spec-
trometry identified both extremely large proteins and 
highly hydrophobic integral membrane proteins. These 
types of brain proteins are usually underrepresented in 
two-dimensional gel electrophoresis. For example, the 
sequence of the 500-kDa intermediate filament-binding 
protein plectin (Q9QXS1) [57] was covered in the wild 
type brain by 18 unique peptides with approximately 5 % 
coverage and in the mdx-4cv brain by 17 unique pep-
tides with approximately 4  % coverage. Remarkably, the 
five main subunits of the plasmalemmal Na+/K+-ATPase 
[58] were all identified in brain extracts. The alpha-1 
(Q8VDN2), alpha-2 (Q6PIE5), alpha-3 (Q6PIC6), beta-1 
(P14094) and beta-2 (P14231) subunits were covered in 
the wild type brain by 13, 17, 20, 9 and 4 unique peptides 
with 20, 21, 27, 19 and 10 % coverage, respectively. These 
findings demonstrate the outstanding performance of the 
LTQ Orbitrap XL mass spectrometer used in this com-
parative whole tissue proteomic study.
Label‑free LC–MS/MS analysis of changed proteins in total 
mdx‑4cv brain extracts
The proteomic comparison of total brain extracts from 
wild type versus mdx-4cv mice using label-free LC–MS/
MS analysis identified 46 affected protein species in the 
dystrophic phenotype (Fig. 1). Table 1 lists the accession 
number, protein name, peptide count, confidence score, 
Anova value and fold change of individual proteins iden-
tified by mass spectrometry. An increased abundance 
was established for 39 proteins and 7 proteins showed a 
decreased concentration. Of considerable interest was 
the proteomic identification of elevated serum proteins, 
especially the confirmation of previously established bio-
markers of muscular dystrophy. Increased proteins that 
are mostly associated with plasma and the extracellular 
space were identified as hemopexin (beta-1B-glycopro-
tein), alpha-2-HS-glycoprotein (fetuin-A), alpha-1-an-
titrypsin 1-1 and 1-2, hemoglobin alpha and beta-1, 
apolipoprotein A-I, albumin and serotransferrin. The 
increase of this class of soluble protein is most likely due 
to disease-related changes in the concentration levels of 
distinct plasma proteins, but could also be partially asso-
ciated with altered capillarisation, local cellular damage, 
disturbed homeostasis, impaired regulatory mechanisms, 
proteolytic processes and/or inflammatory responses.
Immunofluorescence microscopy of brain sections 
using an antibody to von Willebrand factor (vWF) indi-
cated changes in the vascularization of the mdx-4cv 
brain (Fig.  2). The dot-shaped labelling of Weibel-Pal-
ade bodies [59], that act as specific intracellular storage 
organelles for vWF molecules in the vessel endothelium 
[60], can be clearly seen as distinct subcellular struc-
tures in normal brain sections (Fig.  2a). Under normal 
conditions, multimeric vWF molecules assemble into 
tubular structures within Weibel-Palade bodies in the 
inner lining of blood vessels. However, when vWF mol-
ecules are released they unfold into strings and play a 
critical role in hemostasis, inflammation, regulation of 
vascular tone and angiogenesis [61]. The mdx-4cv brain 
showed, besides punctate Weibel-Palade bodies, also a 
large number of string-like structures that contain vWF 
molecules (Fig. 2b). Since this type of transformation is 
indicative of a response of the endothelium to patho-
physiological changes in its micro environment [60], 
dystrophin deficiency appears to trigger the subcellular 
translocation of Weibel-Palade bodies and the release 
of vWF. Therefore structural distension, vascular dam-
age and inflammatory processes appear to exist at the 
blood-tissue interface in the mdx-4cv brain. This would 
agree with the cell biological analysis of tight junc-
tion and glial markers in the mdx brain, which showed 
that microvessels are lined by altered endothelial cells 
with open tight junctions and swollen glial processes. 
The perivascular glial endfeet zone was shown to con-
tain cellular debris and was enveloped by degenerating 
microvessels [62].
The approximately fivefold increase of hemopexin, an 
abundant serum glycoprotein that binds free heme, is a 
well-established disease indicator in the plasma from 
Duchenne muscular dystrophy patients and carriers of 
this neuromuscular disorder [63, 64]. Since serotrans-
ferrin is responsible for the efficient binding and trans-
portation of iron throughout the circulatory system [65], 
its increased concentration could be linked to an altered 
iron metabolism in the mdx-4cv brain. The elevated levels 
of haemoglobin and albumin suggest a potential shift to 
higher levels of oxygen supply and fatty acid utilization. 
Interestingly, antitrypsin appears to be increased in brain 
tissue. This serum protein functions both as a protec-
tive anti-protease and a crucial anti-inflammatory factor 
[66], suggesting the triggering of a protective mechanism 
within Dp427-lacking tissue in response to neuronal 
degeneration and brain inflammation. The identification 
of fetuin-A also agrees with the pathological status of 
the mdx-4cv mouse, since this multi-functional protein 
has been previously identified as a general biomarker for 
neurodegenerative disease [67].
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Table 1 Changed proteins in mdx-4cv brain tissue as revealed by label-free LC–MS/MS analysis
Accession number Protein name Peptide count Confidence score Anova (p) Fold change
Q91X72 Hemopexin 3 131.20 0.00116 5.64
P29699 Alpha-2-HS-glycoprotein 2 125.19 0.00171 3.47
P22599 Alpha-1-antitrypsin 1-2 2 114.76 0.01445 3.29
P02088 Hemoglobin subunit beta-1 3 260.19 0.00104 3.24
P01942 Hemoglobin subunit alpha 5 370.80 0.00021 3.22
Q00623 Apolipoprotein A-I 8 316.96 0.00522 2.88
P07758 Alpha-1-antitrypsin 1-1 4 108.27 0.01739 2.52
P07724 Serum albumin 16 1174.47 0.00049 2.51
Q923D2 Flavin reductase (NADPH) 3 203.95 0.00171 2.51
Q921I1 Serotransferrin 8 374.58 0.01661 2.18
P03995 Glial fibrillary acidic protein 8 491.51 0.03531 2.00
Q08331 Calretinin 2 94.24 0.04022 1.93
P48036 Annexin A5 2 132.70 0.03204 1.56
P20152 Vimentin 2 213.31 0.00440 1.55
Q9R0P9 Ubiquitin carboxyl-terminal hydrolase isozyme L1 3 165.79 0.02308 1.51
P46460 Vesicle-fusing ATPase 2 134.05 0.00110 1.44
Q9D0E1 Heterogeneous nuclear ribonucleoprotein M 3 63.46 0.01490 1.44
O08788 Dynactin subunit 1 2 126.53 0.01025 1.44
P38647 Stress-70 protein, mitochondrial 6 476.79 0.00175 1.42
P48758 Carbonyl reductase [NADPH] 1 2 119.09 0.01333 1.42
P00920 Carbonic anhydrase 2 2 135.96 0.02814 1.42
P14733 Lamin-B1 2 150.58 0.02918 1.41
Q6IRU5 Clathrin light chain B 2 125.00 0.04203 1.40
Q8R3V5 Endophilin-B2 4 201.90 0.02055 1.39
Q8QZT1 Acetyl-CoA acetyltransferase, mitochondrial 4 215.23 0.00680 1.36
P27773 Protein disulfide-isomerase A3 5 295.10 0.01295 1.35
Q91VR2 ATP synthase subunit gamma, mitochondrial 4 251.82 0.00255 1.35
Q6ZWY9 Histone H2B type 1-C/E/G 2 121.60 0.04212 1.34
Q61171 Peroxiredoxin-2 2 141.40 0.01279 1.33
Q9D051 Pyruvate dehydrogenase E1 component subunit beta, mito-
chondrial
4 262.12 0.00408 1.32
O35737 Heterogeneous nuclear ribonucleoprotein H 2 100.27 0.01665 1.31
Q03265 ATP synthase subunit alpha, mitochondrial 6 480.06 0.00581 1.30
P20029 78 kDa glucose-regulated protein 2 150.07 0.02510 1.29
Q9QXS6 Drebrin 3 142.38 0.01934 1.28
P62259 14-3-3 protein epsilon 2 103.43 0.02864 1.27
O88737 Protein bassoon 3 215.46 0.01328 1.25
Q811D0 Disks large homolog 1 2 110.76 0.00639 1.25
P14873 Microtubule-associated protein 1B 2 126.07 0.00500 1.24
P16546 Spectrin alpha chain, non-erythrocytic 1 3 197.38 0.01491 1.24
P61264 Syntaxin-1B 4 356.83 0.00121 −1.28
Q02053 Ubiquitin-like modifier-activating enzyme 1 2 131.59 0.04436 −1.41
P51150 Ras-related protein Rab-7a 3 106.89 0.01101 −1.51
P07901 Heat shock protein HSP 90-alpha 2 109.14 0.03836 −1.54
O08599 Syntaxin-binding protein 1 4 315.93 0.01966 −1.54
Q9WV92 Band 4.1-like protein 3 3 218.67 0.00892 −1.90
Q9R0K7 Plasma membrane calcium-transporting ATPase 2 2 108.25 0.01784 −2.77
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Altered brain tissue‑associated proteins in the mdx‑4cv 
mouse model of dystrophinopathy
Interesting brain tissue-associated proteins with an 
increased concentration in the mdx-4cv animal model of 
Duchenne muscular dystrophy were represented by flavin 
reductase, glial fibrillary acidic protein GFAP, the neuronal 
Ca2+-binding protein calretinin, annexin AnxA5, vimentin, 
the neuron-specific enzyme ubiquitin carboxyl-terminal 
hydrolase isozyme L1, vesicle-fusing ATPase, heterogene-
ous nuclear ribonucleoproteins M and H, dynactin, the 
75 and 78  kDa glucose-regulated proteins (mitochondrial 
chaperones HspA9/GRP-75 and HspA5/Grp78), carbonyl 
reductase, carbonic anhydrase CA2, lamin-B1, clathrin, 
endophilin-B2, mitochondrial acetyl-CoA acetyltrans-
ferase, protein disulfide-isomerase PDI-A3, mitochondrial 
ATP synthase (alpha and gamma subunits), histone H2B, 
peroxiredoxin PRDX2, mitochondrial pyruvate dehydro-
genase, the dendritic spine protein drebrin, 14-3-3 protein 
epsilon, the cytomatrix protein bassoon of the nerve ter-
minals active zone, the synapse-associated protein SAP97 
(disks large homolog 1), microtubule-associated protein 1B 
and spectrin (Table 1). Decreased brain proteins were iden-
tified as the nervous system-specific proteins syntaxin-1B 
and syntaxin-binding protein 1, as well as the plasma mem-
brane Ca2+-transporting ATPase PMCA2 that is mostly 
found in the brain cortex. Other reduced brain-associ-
ated proteins included ubiquitin-like modifier-activating 
enzyme 1, ras-related protein Rab-7a, heat shock protein 
HSP 90-alpha (HSP90AA1) and 4.1-like protein 3 (Table 1).
Distribution of protein changes in mdx‑4cv brain tissue
The distribution pattern of proteome-wide changes in 
mdx-4cv brain tissue in relation to altered protein classes 
is shown in Fig. 3. A standard bioinformatics software pro-
gramme was used to illustrate overall protein changes. The 
application of the PANTHER analysis tool [68] revealed 
a certain degree of clustering of mass spectrometrically 
identified proteins with a changed concentration in mdx-
4cv brain tissues. The most drastic alterations were shown 
to affect cytoskeletal proteins (14.3 %), which would agree 
with the underlying primary genetic abnormality in the 
membrane cytoskeletal component dystrophin. Consider-
able changes were shown to occur in the molecular classes 
of transfer/carrier proteins (10.7  %), hydrolases (8.9  %), 
enzyme modulators (7.1 %), molecular chaperones (7.1 %), 
transporters (7.1 %), oxidoreductases (7.1 %), nucleic acid 
binding proteins (7.1 %), membrane traffic proteins (5.4 %) 
and structural proteins (5.4 %). Relatively minor variations 
were identified for proteases (3.6  %), transferases (3.6  %), 
lyases, (3.6 %), receptors (1.8 %), transmembrane receptor 
regulatory/adaptor proteins (1.8 %), Ca2+-binding proteins 
(1.8  %), extracellular matrix proteins (1.8  %) and ligases 
(1.8 %). Select proteomic findings were further analysed by 
immunoblotting and immunofluorescence microscopy in 
order to independently verify the results from the compar-
ative label-free LC–MS/MS study of brain tissue extracts 
from wild type versus mdx-4cv mice.
Elevated levels of glial fibrillary acidic protein 
agrees with the pathobiochemical concept 
of neurodegeneration‑related astrogliosis in the mdx‑4cv 
brain
The twofold increase of the glial fibrillary acidic pro-




Fig. 2 Immunofluorescence microscopical analysis of von Willebrand 
factor in normal versus mdx-4cv brain. Shown is the immunofluores-
cence labelling of brain sections using an antibody to von Willebrand 
factor (vWF) in wild type a versus mdx-4cv b cortex. Dot-like staining 
patterns are seen in both normal and mdx-4cv brain sections and rep-
resent Weibel-Palade bodies [61] that function as intracellular storage 
organelles for vWF molecules in the vessel endothelium. The mdx-4cv 
brain shows also a large number of string-like structures that contain 
vWF molecules, which is indicative of structural alterations, vascular 
damage and inflammatory processes at the blood-tissue interface in 
the mdx-4cv brain. Bar equals 10 μm
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coverage (Fig.  1), is an interesting proteomic finding of 
considerable pathobiochemical importance [69]. This 
brain protein is often referred to as GFAP [70] and func-
tions as a major intermediate filament component that is 
specifically associated with astrocytes in the central nerv-
ous system [71]. Importantly, an increased concentration 
of GFAP is an established indicator of glial scar formation 
in the field of neuropathology [72–74]. The independent 
verification of expression changes in GFAP in mdx-4cv 
brain tissue was carried out by both immunoblot analysis 
and immunofluorescence microscopy. Figure 4 illustrates 
the specificity of the antibody to GFAP used in immuno-
blotting. While the nuclear envelope marker lamin and 
the cytosolic enzyme lactate dehydrogenase are present 
in crude extracts from mouse liver, diaphragm, heart, 
leg muscles and brain tissue (Fig. 4b, c), GFAP was only 
detected in brain specimens (Fig. 4d). A silver-stained gel 
of the protein extracts from different tissues is presented 
in Fig.  4a. The immuno-labelling of GFAP molecules 
often results in the recognition of more than one band 
in one-dimensional gel electrophoresis. An immunob-
lot study of GFAP by Singh et al. [75] has shown a tight 
banding pattern of this glial marker with 2–3 protein 
bands with slightly differing electrophoretic mobility. In 
analogy, the antibody decoration of increasing amounts 
of mouse brain protein per gel lane, as shown in Fig. 4e, 
demonstrated that a broader immuno-labelled GFAP 
banding pattern occurs at higher protein amounts. Based 
on these findings, an intermediate amount of brain pro-
tein was used per lane for comparative studies.
The expression changes of GFAP in mdx-4cv brain tis-
sue, as indicated by comparative proteomic profiling 
(Table  1), was confirmed by immunoblotting as illus-
trated in Fig. 5. The concentration of GFAP was found to 
be significantly elevated in the mdx-4cv brain. Standard 
gel electrophoretic analyses showed no major changes in 
the protein band pattern of wild type versus dystrophic 
preparations (Fig. 5a, f, i). In contrast to the expression of 



































Fig. 3 Overview of changed protein classes in total tissue extracts from the mdx-4cv brain. In order to identify the clustering of protein classes 
based on the mass spectrometric analysis of crude extracts from wild type versus mdx-4cv brain specimens (Table 1), the bioinformatics software 
programme PANTHER [68] was used
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lactate dehydrogenase (used as a loading control), which 
does not appear to be affected in the Dp427-deficient 
brain (Fig. 5b, d, g, j), the abundance of the glia marker 
GFAP was shown to be significantly increased in 2- to 
12-month old mdx-4cv mice (Fig. 5c, e, h, k). The cell bio-
logical analysis of GFAP levels by immunofluorescence 
microscopy also confirmed the proteomic analysis of the 
mdx-4cv brain. As shown in Fig. 6, the cortex displayed 
a substantially higher labelling of GFAP in the dystro-
phin-deficient brain as compared to wild type. These 
immunoblotting and immunofluorescence microscopical 
results substantiated the proteomic findings presented in 
Table 1 and agree with the idea of progressive astroglio-
sis as a consequence of progressive neurodegeneration 
in the mdx-4cv brain. Thus, the GFAP elevation prob-
ably reflects non-specific reactive gliosis [69–71] and the 
resulting glial scar formation may be linked to impaired 
brain functions in the mdx mouse and Duchenne 
patients [46]. The constant loss of neurons and concomi-
tant proliferation or hypertrophy of glial cells may be the 
underlying mechanism that triggers developmental cog-
nitive deficits and behavioural abnormalities in Duch-
enne muscular dystrophy [45–47]. A previous case report 
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Fig. 4 Immunoblot analysis of the tissue-specific expression of the glial fibrillary acidic protein GFAP. Shown is a silver-stained gel (a) and corre-
sponding immunoblots labelled with antibodies to the nuclear envelope protein lamin B1 (b), the cytosolic enzyme lactate dehydrogenase (c; LDH) 
and the glial fibrillary acidic protein (d; GFAP). Lanes 1–5 contain crude extracts from mouse liver, diaphragm, heart, leg muscle and brain, respec-
tively. While lamin and lactate dehydrogenase were detected in all five tissues studied, GFAP could only be detected in brain samples, demonstrat-
ing the tissue-specific recognition of this protein by the antibody ab7260 to GFAP. Antibody labelling of increasing amounts of mouse brain protein 
per gel lane showed that a broader immuno-labelled GFAP banding pattern occurs at higher protein amounts (e). Lanes 6–13 contained 0, 2, 5, 10, 
20, 40, 60 and 80 μg protein/lane, respectively
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described multifocal glial nodules in the cerebral cortex. 
Proliferating glial cells showed intense immunoreactiv-
ity for GFAP and were suggested to be at least partially 
involved in the pathogenic mechanisms of mental retar-
dation [76].
Proteomic profiling suggests abnormal calcium handling, 
cytoskeletal restructuring and metabolic changes  
in the mdx‑4cv brain
The previous biochemical and cell biological characteri-
zation of the brain from dystrophic mdx mice has dem-
onstrated intricate changes in the development of the 
blood–brain barrier [62, 77], the regulation of the extra-
cellular matrix [78] and the molecular arrangements 
within the glial dystrophin-associated signalling complex 
that contains the water channel aquaporin AQP4, the K+-
channel Kir-4.1 and agrin [79]. This suggests multifaceted 
cellular rearrangements within the dystrophin-lacking 
brain and the proteomic findings presented here have 
confirmed this complexity of pathobiochemical altera-
tions. Noteworthy brain tissue-associated proteins with 
an increased concentration in the mdx-4cv animal model, 
besides the glial fibrillary acidic protein GFAP, were iden-
tified as the AnxA5 isoform of annexin, the intermedi-
ate filament protein vimentin and the nuclear envelope 
protein lamin LAM-B1. The immunoblot analysis pre-
sented in Fig. 7a–c, e–g confirmed the general tendency 
of higher levels of these proteins, although only changes 
in annexin and vimentin were shown to be significant. In 
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Fig. 5 Comparative immunoblot analysis of the glial fibrillary acidic protein GFAP in normal versus mdx-4cv brain. Shown are representative silver-
stained gels (a, f, i) and immunoblots (b, c, g, h, j, k). Panels a–c contain 12-month old wild type (wt) and mdx-4cv brain specimens, and panels f–k 
show 2-, 8- and 12-month old samples. Blots were labelled with antibodies to lactate dehydrogenase (LDH as loading control) (b, g, j), and the glial 
fibrillary acidic protein (GFAP) (c, h, k). Arrowheads mark the main immuno-labelled protein bands in individual panels. Graphical representations of 
the immuno-decoration levels for LDH and GFAP in 12-month old wt versus mdx-4cv brain are shown in panels d and e: Student’s t test, unpaired; 
n = 4; *p < 0.05
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[80], the up-regulation of annexin probably represents 
a subcellular repair mechanism involved in membrane 
maintenance [81] and elevated vimentin levels could 
function as cytoskeletal stabilization in the absence of 
brain dystrophin. Alternatively, vimentin changes may be 
linked to astrogliosis-related alterations in the interme-
diate filament system. Astrocyte activation and reactive 
gliosis in the damaged central nervous system has previ-
ously shown to be associated with the increased produc-
tion of cytoskeletal proteins and rearrangements within 
the intermediate filament system of astrocytes [82].
In addition, the proteomic profiling of the mdx-4cv 
brain indicated metabolic adaptations, disturbed ion 
handling and functional changes in the central nervous 
system from the dystrophic phenotype. The immunob-
lotting analysis of the plasma membrane Ca2+-trans-
porting ATPase 2 (Fig. 7d, h), which is mainly expressed 
in brain cortex, confirmed the proteomic identification 
of significantly reduced PMCA2 levels (Table  1). The 
Ca2+-pump activities of PMCA2 complexes are criti-
cal regulators of dendritic ion homeostasis that con-
trols Purkinje cell dendritic growth [83]. In contrast to 
PMCA2, the Ca2+-binding protein calretinin [84] was 
shown to be significantly increased in the mdx-4cv brain 
(Table  1), possibly compensating abnormal calcium 
fluxes within specific neurons of the central nervous sys-
tem. Interesting proteomic biomarker candidates with 
a differential expression pattern are the neuron-specific 
enzyme ubiquitin carboxyl-terminal hydrolase isozyme 
L1, the dendritic spine protein drebrin, the cytomatrix 
protein bassoon of the nerve terminal active zone, and 
the synapse-associated protein SAP97, as well as the 
nervous system-specific proteins syntaxin-1B and syn-
taxin-binding protein 1 [85].
Conclusions
The comparative proteomic profiling of wild type versus 
mdx-4cv brain extracts has resulted in the biochemi-
cal identification of a large number of proteins with a 
changed concentration. These novel proteomic candi-
dates can now be evaluated for their suitability to estab-
lish a robust biomarker signature of brain pathology 
in Duchenne muscular dystrophy. In the future, brain-
associated or brain-released protein biomarkers might be 
useful as predictive, diagnostic, prognostic and/or ther-
apy-monitoring detection tools for the swift evaluation of 
brain abnormalities in dystrophinopathies. The scale of 
proteome-wide changes described in this report suggests 
complex molecular and cellular changes in the mdx-4cv 
brain that appear to be linked to both progressive neu-
ron degeneration and reactive gliosis. Of special interest 
is the proteomic identification of the glial fibrillary acidic 
protein GFAP, which presents a major intermediate fila-
ment protein of mature astrocytes and an established 
biomarker of astrogliosis. Hence, its significant increase 
in the mdx-4cv brain agrees with the histopathological 
concept of reactive gliosis in the Dp427-deficient cen-
tral nervous system. In addition, the up-regulation of the 
annexin isoform AnxA5 and vimentin suggest compensa-
tory mechanisms at the level of plasma membrane repair 
mechanisms and cytoskeletal re-stabilization. Disturbed 
neuronal proteins involved in Ca2+-handling, metabo-
lism and signalling in the central nervous system illus-
trate the complexity of the molecular pathogenesis in the 
dystrophic phenotype.




Fig. 6 Immunofluorescence microscopical analysis of the glial 
fibrillary acidic protein in normal versus mdx-4cv brain. Shown is the 
immunofluorescence labelling of brain sections using an antibody 
to glial fibrillary acidic protein (GFAP) in wild type a versus mdx-4cv 
b cortex. The mdx-4cv cortex exhibited a substantially higher level 
of GFAP labelling, which agrees with the findings from the mass 
spectrometric analysis and immunoblotting of the mdx-4cv brain. Bar 
equals 50 μm
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Methods
Materials
Whole tissue proteomics for the comparative profil-
ing of mdx-4cv versus wild type brain was conducted 
using analytical grade reagents and materials obtained 
from GE Healthcare (Little Chalfont, Buckinghamshire, 
UK) and Bio-Rad Laboratories (Hemel-Hempstead, 
Hertfordshire, UK). A number of other chemicals were 
used in this mass spectrometry-based survey, includ-
ing ultrapure acrylamide stock solutions which were 
purchased from National Diagnostics (Atlanta, GA, 
USA), sequencing grade modified trypsin and Lys-C 
obtained from Promega (Madison, WI, USA) and What-
man nitrocellulose transfer membranes from Invitrogen 
(Carlsbad, CA, USA). The chemiluminescence substrate 
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Fig. 7 Comparative immunoblot analysis of normal versus mdx-4cv brain. Shown are representative immunoblots (a–d) of key proteomic hits iden-
tified by mass spectrometric analysis. Lanes 1 and 2 represent total extracts from control wild type (wt) and mdx-4cv brain, respectively. Blots were 
labelled with antibodies to the AnxA5 isoform of annexin (a), the intermediate filament protein vimentin (VIM) (b), the nuclear envelope protein 
lamin B1 (LAM-B1) (c) and the plasma membrane Ca2+-ATPase isoform PMCA2 (d). Arrowheads mark the main immuno-labelled protein bands in 
individual panels. Graphical representations of the immuno-decoration levels are shown in panels e–h: Student’s t-test, unpaired; n = 4; *p < 0.05; 
**p < 0.01; ***p < 0.001
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Diagnostics (Mannheim, Germany). Superfrost Plus 
positively-charged microscope slides were from Menzel 
Glaesser (Braunschweig, Germany). Primary antibodies 
were purchased from Abcam, Cambridge, UK (ab14196 
to annexin Anx5; ab7260 to glial fibrillary acidic protein 
GFAP; ab16048 to lamin-B1; ab3529 to the Ca2+-ATPase 
PMCA2; and ab52488 to lactate dehydrogenase) and 
Dako (Agilent Technologies), Hamburg, Germany (Rab-
bit polyclonal antibodies Z033429 to glial fibrillary acidic 
protein GFAP and A0082 to von Willebrand factor vWF). 
Chemicon International (Temecula, CA, USA) provided 
peroxidase-conjugated secondary antibodies. Normal 
goat serum and Cy3-conjugated goat anti-rabbit antibod-
ies were from Jackson ImmunoResearch (West Grove, 
PA, USA). A range of other general chemicals were used, 
all of which were analytical grade and were obtained 
from Sigma Chemical Company (Dorset, UK).
Dystrophic mdx‑4cv mouse model of X‑linked 
dystrophinopathy
A deeper understanding of the pathobiochemistry 
of Duchenne muscular dystrophy has been greatly 
enhanced by the systematic proteomic profiling of estab-
lished animal models [54]. The conventionally used mdx 
mouse [86] in particular has been extensively used [87]. 
This genetic model, in analogy to the human condition, is 
almost completely lacking the full-length Dp427 isoform 
of dystrophin. Behavioural studies have shown signifi-
cant differences in the retention of the passive avoidance 
response [48], long delays in spontaneous alternation 
and bar-pressing tasks [49] and impaired long-term spa-
tial and recognition memory [50] in the mdx mouse. The 
impairment in passive avoidance learning and behav-
ioural changes in mdx mice indicates that the loss of 
brain dystrophin is associated with cognitive dysfunc-
tions. In relation to behavioural/neurological aspects 
of the mdx-4cv strain, the Mouse Genome Information 
site from Jackson Laboratory states that this dystrophic 
mouse model exhibits abnormal grip strength and that 
the determined grip strength is weaker than that of wild 
type and the mdx-3cv mouse (http://www.informatics.
jax.org). This analysis indicates that muscular weakness 
and potentially behavioural deficits exist in the mdx-4cv 
mouse model of Duchenne muscular dystrophy. Impor-
tantly, the mdx-4cv mouse [88] displays ten-fold fewer 
revertant dystrophin-positive fibres [89] and immunob-
lotting has shown the absence of the shorter Dp140 and 
Dp260 isoforms, as well as the full-length brain, Purkinje 
and muscle Dp427 isoforms [90]. This renders the mdx-
4cv mouse a more suitable model system for the study of 
new therapeutic avenues, such as exon skipping or stop-
codon read-through therapy [91]. In order to investigate 
the effect of Dp427 deficiency on protein expression 
patterns in the central nervous system, whole brains were 
removed from 2-, 8- and 12-month old mdx-4cv mice 
and aged-matched control C57BL6 mice. All animals 
used in this study were housed at the Bioresource Unit at 
the University of Bonn [92], where they were kept under 
standard conditions according to German and Irish leg-
islation on the use of animals in experimental research. 
The animals were sacrificed by cervical dislocation and 
all tissue samples were immediately isolated [93].
Preparation of tissue extracts from mdx‑4cv and wild type 
brain for proteomic analysis
Brain samples from 12-month old wild type (wt) (n = 4) 
and mdx-4cv (n  =  4) animals were freshly dissected, 
quick-frozen in liquid-nitrogen and stored at −80  °C 
prior to usage. Freshly thawed brain tissue (100  mg) 
was finely chopped and homogenised in 10 volumes 
of homogenisation buffer (8  M urea, 50  mM Tris–HCl 
pH 8.0, 1 mM EDTA) using a hand-held IKA T10 Basic 
Homogeniser (IKA Labortechnik, Staufen, Germany). To 
limit potential protein degradation by protease activity, 
this buffer was supplemented with a protease inhibitor 
cocktail from Roche Diagnostics (Mannheim, Germany). 
Brain homogenates were incubated at 4  °C for 1.5  h 
with gentle shaking using a Thermomixer from Eppen-
dorf (Hamburg, Germany). Samples were centrifuged at 
14,000×g for 20  min at 4  °C, and the urea-soluble pro-
tein-containing middle layer was isolated for proteomic 
analysis [94].
Preparation of tissue extracts from liver, diaphragm, leg 
muscle, heart and brain
In order to investigate the tissue-specificity of the anti-
body to GFAP, comparative immunoblotting was 
employed. For this purpose a variety of mouse tissue 
types were used, including liver, heart, hind limb skel-
etal muscles, diaphragm and brain. All samples were 
from control wild type mice. For the preparation of total 
extracts from liver, skeletal muscle and diaphragm, 50 mg 
of tissue samples were finely chopped and homogenised 
in 0.5  ml of homogenisation buffer (20  mM sodium 
pyrophosphate, 20 mM sodium phosphate, 1 mM MgCl2, 
0.303 M sucrose, 0.5 mM EDTA, pH 7.0), using a hand-
held IKA T10 Basic Homogeniser (IKA Labortechnik, 
Staufen, Germany) [93]. Similarly, 50  mg of heart and 
brain samples were finely chopped and homogenised 
in lysis buffer (7  M urea, 2  M thiourea, 4  % CHAPS, 
2  % DTT, 2  % IPG buffer pH 3–10) and homogenisa-
tion buffer (8  M urea, 50  mM Tris–HCl pH 8.0, 1  mM 
EDTA), respectively [94]. All buffers were supplemented 
with a protease inhibitor cocktail from Roche Diagnos-
tics (Mannheim, Germany) to minimise protein degra-
dation. Protein extracts were gently shaken at 4  °C for 
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1.5  h using a Thermomixer from Eppendorf (Hamburg, 
Germany). Following centrifugation at 14,000g for 20 min 
at 4  °C, the supernatant fractions were isolated and the 
protein concentrations were determined by the method 
of Bradford [95]. Samples were then used for comparative 
immunoblotting.
Sample preparation for label‑free liquid chromatography 
mass spectrometry
Prior to mass spectrometric analysis, protein samples 
were pre-treated with the Ready Prep 2D clean up kit 
from Bio-Rad Laboratories (Hemel-Hempstead, Hert-
fordshire, UK). This removed contaminating agents, 
which may otherwise interfere with the mass spectro-
metric analysis. The pellets obtained from this proce-
dure were resuspended in label-free solubilisation buffer 
(6 M urea, 2 M thiourea, 10 mM Tris, pH 8.0 in LC–MS 
grade water), and samples were vortexed and sonicated 
to aid full resuspension [93]. Protein concentrations were 
determined by the method of Bradford [95] and sam-
ple volumes were equalised with label-free solubilisa-
tion buffer. Samples were treated with 10  mM DTT for 
30  min at 37  °C as a means of reducing protein disul-
phide bonds. Cysteine residues were alkylated by adding 
iodoacetamide to a concentration of 25  mM in 50  mM 
ammonium bicarbonate and incubating for 20  min in 
the dark. To limit the possibility of trypsin alkylation by 
unreacted iodoacetamide, samples were further reduced 
with 10  mM dithiothreitol for 15  min in the dark. Pro-
tein digestion was carried out in two steps. Firstly pro-
teolytic digestion was carried out with sequencing grade 
Lys-C at a ratio of 1:100 (protease:protein) at 37 °C for 4 h 
with agitation. Following the initial cleavage of peptide 
bonds, samples were diluted with four times the initial 
sample volume in 50  mM ammonium bicarbonate. The 
final stage of protein digestion was achieved by incuba-
tion with sequencing grade trypsin overnight at 37 °C at 
a ratio of 1:25 (protease:protein). Acidification with 2 % 
trifluoroacetic acid (TFA) in 20 % acetonitrile (ACN) [3:1 
(v/v) dilution] terminated protein digestion. The sample 
digests were purified with Pierce C18 Spin Columns from 
Thermo Fisher Scientific (Dublin, Ireland), dried through 
vacuum centrifugation and resuspended in loading buffer 
consisting of 2 % ACN and 0.05 % TFA in LC–MS grade 
water. To ensure the even suspension of peptides, sam-
ples were vortexed and sonicated prior to loading on the 
mass spectrometer.
Label‑free liquid‑chromatography mass spectrometric 
analysis
The nano LC–MS/MS analysis of mdx-4cv versus wt 
brain tissue was carried out with an Ultimate 3000 
nanoLC system (Dionex) coupled to an LTQ Orbitrap 
XL mass spectrometer (Thermo Fisher Scientific) in the 
Proteomics Facility of the National Institute for Cellular 
Biotechnology, Dublin City University, using optimised 
methodology [96]. Digested peptide samples (5  µl vol-
ume) were loaded onto a C18 trap column (C18 PepMap, 
300 μm id × 5 mm, 5 μm particle size, 100 Å pore size; 
Dionex). Desalting was performed at a flow rate of 25 μl/
min in 0.1 % TFA/2 % ACN for 10 min. The trap column 
was then switched on-line with an analytical PepMap 
C18 column (75 μm id × 500 mm, 3 μm particle and 100 
Å pore size; Dionex). Brain-tissue derived peptides were 
eluted with the following binary gradients: solvent A [2 % 
(v/v) ACN (acetonitrile) and 0.1  % (v/v) formic acid in 
LC–MS grade water] and 0–25 % solvent B [80 % ACN 
and 0.08 % (v/v) formic acid in LC–MS grade water] for 
240  min and 25–50  % solvent B for a further 60  min, 
with a column flow rate set to 350 nl/min [86]. Data were 
acquired with Xcalibur software, version 2.0.7 (Thermo 
Fisher Scientific). The MS apparatus was operated in 
positive, data-dependent mode and was externally cali-
brated. Survey MS scans were attained in the 400–1200 
m/z range with the resolution set to a value of 30,000 at 
m/z 400 and lock mass set to 445.120025u. Collision-
induced dissociation (CID) fragmentation was carried 
out with the three most intense ions per scan. A dynamic 
exclusion window was applied within 60  s [97]. A nor-
malized collision energy of 35 %, an isolation window of 3 
m/z and one microscan were used to collect suitable tan-
dem mass spectra.
Quantitative mass spectrometric identification 
of brain‑derived proteins
The raw data obtained from the LC–MS/MS analysis was 
processed using Progenesis QI for Proteomics software 
(version 2.0; Non-Linear Dynamics, a Waters company, 
Newcastle upon Tyne, UK). Crucially the LC retention 
times of all data were aligned to an assigned reference 
run (run with the most peptides), to allow for any drift 
in retention time [95]. Prior to exportation to Proteome 
Discoverer 1.4 (Thermo Scientific), the MS/MS data files 
were filtered using the following parameters; (1) pep-
tide features with ANOVA ≤  0.05 between experimen-
tal groups, (2) mass peaks with charge states from +1 
to +5 and (3) greater than one isotope per peptide. The 
PepXML generic file, generated from all exported MS/
MS spectra, was used for peptide identification using 
Proteome Discoverer 1.4 against Mascot (version 2.3, 
Matrix Science, Boston, MA, USA) and Sequest HT 
(SEQUEST HT algorithm, licence Thermo Scientific, reg-
istered trademark University of Washington, USA) and 
searched against the UniProtKB-SwissProt database (tax-
onomy: Mus musculus). The following search parameters 
were used for protein identification: (1) peptide mass 
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tolerance set to 20  ppm, (2) MS/MS mass tolerance set 
to 0.6 Da, (3) up to two missed cleavages were allowed, 
(4) carbamidomethylation set as a fixed modification and 
(5) methionine oxidation set as a variable modification 
[97]. For re-importation back into Progenesis LC–MS 
software for further analysis, only peptides with either 
ion scores of 40.00 or more (from Mascot) and peptides 
with XCorr scores >1.9 for singly charged ions, >2.2 for 
doubly charged ions and >3.75 for triply charged ions 
or more (from Sequest HT) were selected. A number of 
criteria were applied to ensure proper identification of 
brain-tissue derived proteins, including an ANOVA score 
between experimental groups of ≤0.05 and proteins with 
≥2 peptides matched.
Bioinformatics analysis of potential protein interactions
The freely available software package PANTHER (http://
pantherdb.org) was used for the bioinformatics analy-
sis of the mass spectrometric findings generated in this 
study [68]. Proteins with an altered expression in mdx-
4cv brain samples were grouped based on their protein 
class using the PANTHER database of protein families.
Independent verification of key proteomic hits 
by immunoblot analysis
In order to confirm alterations in protein expression, as 
identified by label-free mass spectrometry, immuno-
blot analysis using a panel of antibodies against select 
proteins was employed. Electrophoretic separation of 
proteins from 2-, 8- and 12-month old wild type and 
mdx-4cv brain tissues, as well as extracts from liver, 
heart, diaphragm and leg muscles, was performed using 
standard 10  % polyacrylamide gels, followed by wet 
transfer at 100 V for 70 min at 4 °C to Whatman Protan 
nitrocellulose sheets in a Transblot Cell from Bio-Rad 
Laboratories (Hemel-Hempstead, Hertfordshire, UK) as 
per standard procedure [98]. Membranes were blocked 
for 1 h at room temperature with a milk protein solution 
[2.5 % (w/v) fat-free milk powder in 10 % phosphate-buff-
ered saline] prior to incubation with primary antibodies 
to limit non-specific binding. Nitrocellulose sheets were 
then incubated with sufficiently diluted primary antibod-
ies overnight at 4  °C with gentle agitation. Membranes 
were subsequently washed twice with the milk protein 
solution for 10  min each time, followed by incubation 
for 1.5  h with peroxidase-conjugated secondary anti-
bodies, diluted in the blocking buffer. Visualisation of 
antibody-labelled protein bands on washed membranes 
was achieved using enhanced chemiluminescence as per 
manufacturer’s guidelines. Densitometric scanning and 
statistical analysis of immunoblots was performed with a 
HP PSC-2355 scanner and ImageJ software (NIH, USA), 
in conjunction with GraphPad Prism software (San 
Diego, CA, USA), in which a p value <0.05 was deemed 
to be statistically significant.
Immunofluorescence microscopy of brain sections
In order to verify the increased abundance of the glial 
fibrillary acidic protein (GFAP) in the Dp427-deficient 
brain, as well as study vascularization by labelling 
brain tissue with von Willebrand factor (vWF), mdx-
4cv versus wild type cortex sections were analysed by 
immunofluorescence microscopy [32]. Brains were 
carefully removed and quick-frozen in liquid nitro-
gen. Cryo-sectioning was used to produce 10  µm sag-
ittal sections, which were placed on Superfrost Plus 
positively-charged microscope slides. Brain sections 
were fixed for 5 min in ice-cold 4 % (v/v) paraformalde-
hyde in phosphate-buffered saline (PBS). Sections were 
then permeabilized in 0.1  % (v/v) Triton X-100 in PBS 
for 30  min at room temperature. Tissue sections were 
blocked in 20 % (v/v) normal goat serum in PBS for 30 
min and incubated overnight at 4  °C with rabbit poly-
clonal antibodies to GFAP (1:300 in PBS) or vWF (1:400 
in PBS). Following a careful washing step, brain sections 
were incubated with Cy3-conjugated anti-rabbit anti-
bodies (1:300) for 30 min at room temperature. Primary 
antibodies were omitted for control staining. Antibody-
labelled brain sections were embedded in Fluoromount 
G medium and viewed under a Zeiss Axioskop 2 epi-
fluorescence microscope equipped with a digital Zeiss 
AxioCam HRc camera (Carl Zeiss Jena GmbH, Jena, 
Germany).
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